Mubadala Capital Ventures
VC Fund
San Francisco, United States
Mubadala Capital Ventures is a VC fund in San Francisco focused on Biotechnology and Health Care. Mubadala Capital’s Ventures business builds on Mubadala’s 10-year track record of being an active investor in advanced technology. The Ventures platform includes a direct investment business, a fund of funds business and the management and oversight of Mubadala’s partnership with SoftBank, including its U.S. $15 billion LP commitment to theSoftBank Vision Fund. The Ventures team is based in Abu Dhabi, San Francisco, and London with strong connectivity to European and Chinese venture capital markets through other Mubadala Capital managed vehicles.
- Total investments:
- 129
- Last investment:
- Lead investor:
- 26%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Mubadala Capital Ventures invests in
Stages Mubadala Capital Ventures invests in
Countries Mubadala Capital Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ibrahim Ajami
|
|||
Abdulla AlBanna
|
|||
Chetna Goyal
|
|||
Khaled Abdulla Al Qubaisi
|
|||
| See all 7 contacts → | |||
Investment Focus
Industry
- Biotechnology 22 (17%)
- Health Care 21 (16%)
- Software 15 (12%)
- Therapeutics 12 (9%)
- Medical 9 (7%)
Stage
- Series A 27 (21%)
- Series B 27 (21%)
- Series C 12 (9%)
- Series D 9 (7%)
- Seed 8 (6%)
Country
- United States 54 (42%)
- United Kingdom 5 (4%)
- Germany 4 (3%)
- Sweden 2 (2%)
- Russian Federation 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ibrahim Ajami
Head of Mubadala Ventures
|
Head of Mubadala Ventures | Total investments: 19 | Find email | |
|
Abdulla AlBanna
Partner
|
Partner | Total investments: 2 | Find email | |
Alasdair Thong
Venture Partner
|
Venture Partner | Total investments: 8 | Find email | |
|
Chetna Goyal
Investment Professional
|
Investment Professional | Total investments: 0 | Find email | |
|
Khaled Abdulla Al Qubaisi
Chief Human Group Capital Officer
|
Chief Human Group Capital Officer | Total investments: 6 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Greenlink
|
Greenlink, a joint venture between Baltic Cable and Equitix, runs a 504MW underwater electrical interconnector that connects Ireland and Great Britain. | $200M / Private Equity / Jun 16, 2026 | |
KOHO Financial
|
KOHO Financial provides an application based banking platform intended to simplify financial products available to everyone. Its platform helps users to complete their day to day banking operations while offering tools such as goals, cash flow projections, group spending, spending insights, and categorizations, enabling users to manage theirexpenses and banking operations on the go. | $93.2M / Series E / Jun 10, 2026 | |
Alloy Therapeutics
|
Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Lexington, Massachusetts. | $40M / Series E / Apr 15, 2026 | |
Tahoe Therapeutics
|
Tahoe Therapeutics develops AI-powered tools to simulate human cell responses and guide drug discovery. It operates a platform called Mosaic that produces large-scale single-cell datasets detailing how drug molecules interact with diverse patient cells, with initial applications in oncology. It open-sources its Tahoe-100M dataset, comprisinghundreds of millions of single-cell profiles, to train AI models that build virtual cell models for therapeutic insights. A recent funding round enabled the creation of an even larger dataset, targeting one billion cell datapoints and one million drug-patient interactions, designed to fuel next-generation precision medicines | $30M / Series A / Aug 11, 2025 | |
Auron Therapeutics
|
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M / Series B / Feb 04, 2025 | |
Firstvet
|
FirstVet is a video consultation platform that connects veterinarians, directly on the user's smartphone, tablet, or computer.The app aims to care about a pet and offers help and advice. It helps users to determine when they need to seek care for a pet suffering from stomach problems. They provide consultation, medicinal prescriptions, andrelated services through both mobile applications and their website. Founded in 2016, the company is headquartered in Stockholm, Stockholms Lan, Sweden by David Prien and Joakim Widigs. | $21.5M / Series C / Jun 24, 2024 | |
Storyblok
|
Storyblok says its CMS provides ‘highly customizable content blocks and visual editing tools’ in n contrast to other headless CMS solutions which are flexible for developers but might be less so for actual editors to edit. | $80.1M / Series C / Jun 04, 2024 | |
|
Storyblok
|
Storyblok says its CMS provides ‘highly customizable content blocks and visual editing tools’ in n contrast to other headless CMS solutions which are flexible for developers but might be less so for actual editors to edit. | $80.1M / Series C / Jun 04, 2024 | |
Arbol
|
Arbol is launching an insurance marketplace that connects weather exposed agricultural entities with capital providers like insurers and asset managers. Arbol’s parametric insurance platform removes information asymmetry and reduces administrative costs by leveraging objective data from satellites and weather stations. | $60M / Series B / Apr 30, 2024 | |
Metsera
|
Metsera operates as a clinical-stage biopharmaceutical company. | $290M / Series A / Apr 18, 2024 | |
| See all 129 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Mubadala Capital Ventures invest in?
Mubadala Capital Ventures invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Series B stage. Most of the 129 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Mubadala Capital Ventures?
Public channels for Mubadala Capital Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mubadala Capital Ventures?
The team at Mubadala Capital Ventures includes Ibrahim Ajami (Head of Mubadala Ventures), Abdulla AlBanna (Partner) and Alasdair Thong (Venture Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
